AcneFree Is Latest In Rash Of NAD Decisions Against University Medical
This article was originally published in The Tan Sheet
University Medical Pharmaceuticals continues to have trouble supporting its competitive marketing claims to the satisfaction of the National Advertising Division
You may also be interested in...
Okla. and Ala. limit PSE sales while Colo. and Hawaii consider NPLEx; Abbott, Biocon team on Indian nutrition R&D; Bunge leaves Solae stake to DuPont; Valeant buys AcneFree; more news In Brief.
The National Advertising Division recommends University Medical Pharmaceuticals discontinue claims that compare the effects of its WrinkleFree Eyes to those of Botox, the Council of Better Business Bureaus division says Aug. 19. NAD says the firm should discontinue claims such as, "Clinically proven to reduce wrinkle appearance up to 85 percent in only 20 minutes" and "Truly effective topical alternative to Botox" because of a lack of evidence. NAD asks that the firm remove before-and-after photographs because the lighting, posing and cosmetic application are different in the first photo. The firm said the photos are not misleading. The Irvine, Calif., firm said it is disappointed with NAD's decision, but will consider the recommendations and modify its advertising accordingly
Perrigo promotes in pricing, planning